1 sept Tan Shit Ate bought 1 mil shares @0.055 Shares price plunged to 0.095 after 2.5 mths later after consolidation. Netx threw 1 mil shares few days ago. Shares price will rise then. :)
Mlabs Systems Berhad was founded following the success of a software development project which began in 1992 in University Sains Malaysia. In 1997 Multimedia Research Lab Sdn Bhd (MLABS) was incorporated as a Private Limited Company in Malaysia to carry out on-going research, development and marketing activities for this software. Over the years with recurring success, the company was listed in Malaysian Stock Exchange under MESDAQ counter in August 2005. Multimedia Research Lab Sdn Bhd then became a fully owned subsidiary of Mlabs Systems Berhad.
Today Mlabs is a multi-million dollar entity that is set to become a global technology player. Mlabs has also heavily invested in new technology and solutions, with several upcoming ground-breaking solutions which is set to change the marketplace.
Dec 11): Trial data from Pfizer Inc with partner BioNTech SE, Moderna Inc and AstraZeneca Plc has shown their experimental vaccines are effective in preventing novel coronavirus infection.
While regulatory processes are underway, few Asian countries expect to receive significant amounts of the vaccines initially. Here are estimated distribution time lines, supply deals announced and clinical trials being held in the region.
Australia
The country has secured around 140 million doses: 53.8 million from AstraZeneca, 51 million from Novavax Inc, 10 million from Pfizer, and 25.5 million from distribution programme COVAX.
It expects delivery of 3.8 million doses of AstraZeneca's vaccine in January and February next year and plans to begin inoculations in March.
China
China has not announced supply deals with Western drugmakers, which instead have partnered with private companies in the country.
AstraZeneca's vaccine may be approved in China by mid-2021 and its Chinese partner Shenzhen Kangtai Biological Products Co Ltd plans annual production capacity of at least 100 million doses by the end of this year.
For the Pfizer/BioNTech vaccine, a unit of Shanghai Fosun Pharmaceutical Group Co Ltd plans a Phase II trial.
Tibet Rhodiola Pharmaceutical Holding Co is bringing in Russian vaccine candidate Sputnik V and plans early and mid-stage trials in China.
China has also approved three vaccine candidates developed by Sinovac Biotech Ltd and state-owned China National Pharmaceutical Group (Sinopharm) for emergency use, and Sinopharm hopes its two candidates will get conditional approval for general use this year.
Japan
Japan has deals to buy 120 million doses from Pfizer/BioNTech in the first half of next year and 120 million from AstraZeneca - the first 30 million of which will be shipped by March 2021 - and 250 million from Novavax.
It is also in talks with Johnson & Johnson and has a deal with Shionogi & Co Ltd.
Experts said vaccine makers would need to conduct at least Phase I and II trials in Japan before seeking approval for use.
South Korea
The country has deals to buy 20 million doses each from AstraZeneca, Pfizer and Moderna and another 4 million doses from Johnson & Johnson's Janssen, enough to cover up to 34 million people.
It will procure additional doses for 10 million people through COVAX.
Inoculation is likely to start in the second quarter of next year to allow time to observe possible side effects.
India
The head of the Serum Institute of India, which makes the AstraZeneca vaccine, said on Nov. 23 the positive late-state trial result of the candidate will allow it to seek emergency use approval by year-end, before securing approval for full introduction by February or March.
India also expects a government-backed vaccine to be launched as early as February. It is also conducting a late-stage trial of Sputnik V.
Taiwan
Taiwan aims to secure around 15 million doses initially, both via the COVAX scheme and by direct purchases from manufacturers, and may buy an additional 15 million doses.
The government has said it hopes to begin vaccinations in the first quarter next year.
Malaysia
The Southeast Asian nation has agreed to buy 12.8 million doses of the Pfizer vaccine, becoming the first country in the region to announce a deal with the U.S. drugmaker after some expressed reservations over the need for the ultra-cold storage that the vaccine requires.
Pfizer will deliver the first batch of 1 million doses in the first quarter of next year.
The Philippines
The archipelago announced a deal on Nov. 27 for 2.6 million doses of the AstraZeneca vaccine and is discussing a possible 1 million more, covering about 1% of a population of 108 million people.
It is also seeking 20 million to 50 million doses from Sinovac and is in talks with others, including Pfizer.
Vaccine makers can seek approval from Philippine regulators even if no clinical trial is conducted in the country.
Indonesia
Southeast Asia's most populous country has secured 125.5 million doses from Sinovac, 30 million from Novavax, is in talks with AstraZeneca and Pfizer to buy 50 million doses each, and expects to get 16 million from COVAX.
Indonesia is testing Sinovac's vaccine and preparing mass vaccination for medical staff and other frontline workers to start as soon as late January.
Vietnam
A government official said COVAX vaccines would cover only 20% of the population and the country is likely to have a chance to secure separate deals soon, as demand is very high.
Bangladesh
Bangladesh signed a deal with India's Serum Institute to buy 30 million doses of the AstraZeneca vaccine.
It also expects to receive 68 million doses from global vaccine alliance GAVI at a subsidised rate, a senior health ministry official said.
Mlabs is proud to share that we have successfully hosted our very first Hybrid EGM for our client on 9/9/2020. Shareholders of the company can opt to join virtually over WebEx Events or physically attend at the EGM venue. This provides more flexibility to shareholders especially those who might not be able to travel to the venue physically.
Yes....got vaccine...according to Good 123 statement, he mentioned that cooperate with Pfizer....may be next week u can see the news which mlab aquire by US gov Joe baden somo..hahahh
Hahaha good123 you're here, been searching u for days and nights, why u stop cmenting on permaju i3 and run to here to vomit everything hahahah fani man
Mlab new substantial shareholders... Good123 and Victor Yong. More powerful than hongkies. Expected to acquire pfizer to distribute vaccine. Will be fortune 500 company in 1 year time. Digitalisation
9.5 sen now CUM consolidation is just only 0.9 sen. And this is after other shareholders having pumped in 54 sen of rights. You're now buying at 9.5 sen when other people had put in 74 sen assuming it went ex for consolidation @ 2 sen.
Someone may be collecting cheap shares from frightened/desperate traders now :)
@ sandrakkc 9.5 sen now CUM consolidation is just only 0.9 sen. And this is after other shareholders having pumped in 54 sen of rights. You're now buying at 9.5 sen when other people had put in 74 sen assuming it went ex for consolidation @ 2 sen. 11/12/2020 3:30 PM
kevinchong Like that will up soon I still hold 5m share at mlab 11/12/2020 3:30 PM
sandrakkc Just like NETX they would push it back to the region of 20 sen at least. 11/12/2020 3:30 PM
When u see those stupid ppl come out comment ask u buy n tell u tis n tat jz be careful la aiyoyo. Dah berapa kali kena tipu mengapa tak jadi bijak sikit!!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
SmallFishThinkBig
68 posts
Posted by SmallFishThinkBig > 2020-12-11 12:05 | Report Abuse
banker throw ticket 4.8m shares 095.. got ppl Q 23m shares nak beli 090. Cepat throw la. dah lama tunggu ni.